-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's PI3Ka franchise with the planned announcement of a pan-mutant selective development candidate in Q2 2025 -- $96.7M in cash and cash equivalents expected to be sufficient to fund operations through multiple anticipated milestones into Q4 2026 BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today reported financial results for the quarter ended Mar

— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 — Expansion of PI3Ka franchise to include a pan-mutant selective program; development candidate expected to be announced in Q2 2025 — $111M in cash and cash equivalents expected to be sufficient to fund operations through multiple PIKture-01 clinical readouts and anticipated milestones into Q4 2026 BOULDER, Colo., March 10, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, to

BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Leerink Partners Global Healthcare Conference, in Miami on Tuesday, March 11, 2025, at 4:20 p.m. ET. A live audio webcast will be available through this link and the Investors section of OnKure's website at www.onkure.com. Following the event, a replay will be availa

-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025 -- Management to host conference call today, December 10, 2024 at 7:00 a.m. CT BOULDER, Colo., Dec. 10, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medi

BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10th. OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. E

BOULDER, Colo., Nov. 05, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure Therapeutics, will present a corporate overview at the Stifel Healthcare Conference, on November 18, 2024 at 1:50 p.m. ET in New York, NY. Stifel Healthcare ConferenceDate:  Monday, November 18, 2024Time:  1:50 p.m. ETFormat:  Corporate PresentationWebcast:  Link     A live webcast of the event can be accessed under "Events" on the Investor's section of the Company's website at www.onkure.com.  A

OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D

Evercore ISI initiated coverage of OnKure Therapeutics with a rating of Outperform

Leerink Partners initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $33.00

Oppenheimer initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $35.00

424B3 - OnKure Therapeutics, Inc. (0001637715) (Filer)

10-Q - OnKure Therapeutics, Inc. (0001637715) (Filer)

8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)

DEFA14A - OnKure Therapeutics, Inc. (0001637715) (Filer)

DEF 14A - OnKure Therapeutics, Inc. (0001637715) (Filer)

424B3 - OnKure Therapeutics, Inc. (0001637715) (Filer)

EFFECT - OnKure Therapeutics, Inc. (0001637715) (Filer)

POS AM - OnKure Therapeutics, Inc. (0001637715) (Filer)

S-8 - OnKure Therapeutics, Inc. (0001637715) (Filer)

424B3 - OnKure Therapeutics, Inc. (0001637715) (Filer)

-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025 -- Management to host conference call today, December 10, 2024 at 7:00 a.m. CT BOULDER, Colo., Dec. 10, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medi

OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D

BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10th. OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. E

SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)